on June 9, 2003
Hypertension. 2003
Published online before print June 9, 2003, doi: 10.1161/01.HYP.0000078490.59735.6E
Published online before print June 9, 2003, doi: 10.1161/01.HYP.0000078490.59735.6E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 26, 2003
From the Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. * To whom correspondence should be addressed. E-mail: furuhasi{at}sapmed.ac.jp.
Abstract--Adiponectin, an adipocyte-derived protein, has been suggested to play an important role in insulin sensitivity. We examined the association between insulin sensitivity (M value) evaluated by the euglycemic-hyperinsulinemic glucose clamp and adiponectin concentrations in 30 essential hypertensives (EHT) and 20 normotensives (NT) and investigated the effect of blockade of the renin-angiotensin system (RAS) on adiponectin concentrations. EHT were divided into 12 insulin-resistant EHT (EHT-R) and 18 non-insulin-resistant EHT (EHT-N) using mean-1 SD of the M value in NT. There were no intergroup differences in age, gender, and body mass index (BMI). EHT-R had significantly higher levels of insulin and triglyceride and lower levels of adiponectin than did NT and EHT-N. EHT-R had higher levels of free fatty acid and lower levels of high-density lipoprotein (HDL) cholesterol than did EHT-N. Adiponectin concentrations were positively correlated with M value and HDL cholesterol and negatively correlated with BMI, insulin, free fatty acid, and triglyceride but not with blood pressure. M value, BMI, and HDL cholesterol were independent determinants of adiponectin concentrations in multiple and stepwise regression analyses. Sixteen EHT were treated with an angiotensin-converting enzyme inhibitor (temocapril, 4 mg/d; n=9) or an angiotensin II receptor blocker (candesartan, 8 mg/d; n=7) for 2 weeks. Treatment with temocapril or candesartan significantly decreased blood pressure and increased M value and adiponectin concentrations but did not affect BMI and HDL cholesterol. These results suggest that hypoadiponectinemia is related to insulin resistance in essential hypertension and that RAS blockade increases adiponectin concentrations with improvement in insulin sensitivity.
Revised on March 19, 2003
Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension
Masato Furuhashi*;
Key words: adiponectin • hypertension, essential • insulin resistance • renin-angiotensin system
This article has been cited by other articles:
 |
|
 |
|
  L. L. Guo, Y. Pan, and H. M. Jin Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1876 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mathieu, P. Poirier, P. Pibarot, I. Lemieux, and J.-P. Despres Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease Hypertension, April 1, 2009; 53(4): 577 - 584. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kohlstedt, C. Gershome, C. Trouvain, W.-K. Hofmann, S. Fichtlscherer, and I. Fleming Angiotensin-Converting Enzyme (ACE) Inhibitors Modulate Cellular Retinol-Binding Protein 1 and Adiponectin Expression in Adipocytes via the ACE-Dependent Signaling Cascade Mol. Pharmacol., March 1, 2009; 75(3): 685 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tagami, H. Yamamoto, K. Moriyama, K. Sawai, T. Usui, A. Shimatsu, and M. Naruse A Selective Peroxisome Proliferator-Activated Receptor-{gamma} Modulator, Telmisartan, Binds to the Receptor in a Different Fashion from Thiazolidinediones Endocrinology, February 1, 2009; 150(2): 862 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., December 2, 2008; 29(24): 2959 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saraheimo, C. Forsblom, L. Thorn, J. Waden, M. Rosengard-Barlund, O. Heikkila, K. Hietala, D. Gordin, J. Frystyk, A. Flyvbjerg, et al. Serum Adiponectin and Progression of Diabetic Nephropathy in Patients With Type 1 Diabetes Diabetes Care, June 1, 2008; 31(6): 1165 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanaka, T. Tsutamoto, H. Sakai, K. Nishiyama, M. Fujii, T. Yamamoto, and M. Horie Effect of atrial natriuretic peptide on adiponectin in patients with heart failure Eur J Heart Fail, April 1, 2008; 10(4): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogawa, T. Mori, K. Nako, T. Ishizuka, and S. Ito Reduced Albuminuria with Sarpogrelate Is Accompanied by a Decrease in Monocyte Chemoattractant Protein-1 Levels in Type 2 Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 362 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fliegner, D. Westermann, A. Riad, C. Schubert, E. Becher, J. Fielitz, C. Tschope, and V. Regitz-Zagrosek Up-regulation of PPAR{gamma} in myocardial infarction Eur J Heart Fail, January 1, 2008; 10(1): 30 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. V. Wang and P. E. Scherer Adiponectin, Cardiovascular Function, and Hypertension Hypertension, January 1, 2008; 51(1): 8 - 14. [Full Text] [PDF]
|
|
|
|
|
|
G. Schillaci, M. Pirro, and E. Mannarino Left Ventricular Hypertrophy Reversal and Prevention of Diabetes: Two Birds With One Stone? Hypertension, November 1, 2007; 50(5): 851 - 853. [Full Text] [PDF]
|
|
|
|
 |
|
 E Krusinova, M Klementova, J Kopecky, P Wohl, L Kazdova, P Mlejnek, M Pravenec, M Hill, and T Pelikanova Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects Eur. J. Endocrinol., October 1, 2007; 157(4): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Femia, M. Kozakova, M. Nannipieri, C. Gonzales-Villalpando, M. P. Stern, S. M. Haffner, and E. Ferrannini Carotid Intima-Media Thickness in Confirmed Prehypertensive Subjects: Predictors and Progression Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2244 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Maahs, L. G. Ogden, J. K. Snell-Bergeon, G. L. Kinney, R. P. Wadwa, J. E. Hokanson, D. Dabelea, A. Kretowski, R. H. Eckel, and M. Rewers Determinants of Serum Adiponectin in Persons with and without Type 1 Diabetes Am. J. Epidemiol., September 15, 2007; 166(6): 731 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marre and A. Leye Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 163 - 173. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Katagiri, T. Yamada, and Y. Oka Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals Circ. Res., July 6, 2007; 101(1): 27 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Y. Bang, J. L. Saver, B. Ovbiagele, Y. J. Choi, S. R. Yoon, and K. H. Lee Adiponectin levels in patients with intracranial atherosclerosis Neurology, May 29, 2007; 68(22): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tsioufis, K. Dimitriadis, M. Selima, C. Thomopoulos, C. Mihas, I. Skiadas, D. Tousoulis, C. Stefanadis, and I. Kallikazaros Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients Eur. Heart J., May 1, 2007; 28(9): 1162 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Lely, J. A. Krikken, S. J. L. Bakker, F. Boomsma, R. P. F. Dullaart, B. H. R. Wolffenbuttel, and G. Navis Low Dietary Sodium and Exogenous Angiotensin II Infusion Decrease Plasma Adiponectin Concentrations in Healthy Men J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1821 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wiecek, M. Adamczak, and J. Chudek Adiponectin--an adipokine with unique metabolic properties Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Shen, J. A. Charlesworth, J. J. Kelly, K. W. Loi, and P. W. Peake Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease Nephrol. Dial. Transplant., January 1, 2007; 22(1): 171 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Negro and H. Hassan The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 243 - 246. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Potenza, F. L. Marasciulo, M. Tarquinio, M. J. Quon, and M. Montagnani Treatment of Spontaneously Hypertensive Rats With Rosiglitazone and/or Enalapril Restores Balance Between Vasodilator and Vasoconstrictor Actions of Insulin With Simultaneous Improvement in Hypertension and Insulin Resistance Diabetes, December 1, 2006; 55(12): 3594 - 3603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Teoh, M. H. Strauss, P. E. Szmitko, and S. Verma Adiponectin and myocardial infarction: a paradox or a paradigm? Eur. Heart J., October 1, 2006; 27(19): 2266 - 2268. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hjelmesaeth, A. Flyvbjerg, T. Jenssen, J. Frystyk, T. Ueland, M. Hagen, and A. Hartmann Hypoadiponectinemia Is Associated with Insulin Resistance and Glucose Intolerance after Renal Transplantation: Impact of Immunosuppressive and Antihypertensive Drug Therapy Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 575 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms Circulation, April 18, 2006; 113(15): 1888 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Hermann, W. Li, H. Dominguez, N. Ihlemann, C. Rask-Madsen, A. Major-Pedersen, D. B. Nielsen, K. W. Hansen, M. Hawkins, L. Kober, et al. Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1001 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Schalkwijk, N. Chaturvedi, M. T. Schram, J. H. Fuller, C. D. A. Stehouwer, and the EURODIAB Prospective Complications Study Group Adiponectin Is Inversely Associated with Renal Function in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, S. H. Han, and M. J. Quon Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Efstathiou, D. I. Tsioulos, A. G. Tsiakou, Y. E. Gratsias, A. V. Pefanis, and T. D. Mountokalakis Plasma Adiponectin Levels and Five-Year Survival After First-Ever Ischemic Stroke Stroke, September 1, 2005; 36(9): 1915 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yusuf, J. B. Ostergren, H. C. Gerstein, M. A. Pfeffer, K. Swedberg, C. B. Granger, B. Olofsson, J. Probstfield, J. V. McMurray, and on behalf of the Candesartan in Heart Failure--Ass Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure Circulation, July 5, 2005; 112(1): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Clasen, M. Schupp, A. Foryst-Ludwig, C. Sprang, M. Clemenz, M. Krikov, C. Thone-Reineke, T. Unger, and U. Kintscher PPAR{gamma}-Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin Hypertension, July 1, 2005; 46(1): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saraheimo, C. Forsblom, J. Fagerudd, A.-M. Teppo, K. Pettersson-Fernholm, J. Frystyk, A. Flyvbjerg, P.-H. Groop, and on behalf of the FinnDiane Study Group Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy Diabetes Care, June 1, 2005; 28(6): 1410 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwashima, T. Katsuya, K. Ishikawa, I. Kida, M. Ohishi, T. Horio, N. Ouchi, K. Ohashi, S. Kihara, T. Funahashi, et al. Association of Hypoadiponectinemia With Smoking Habit in Men Hypertension, June 1, 2005; 45(6): 1094 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Juan, Y. Chien, L.-Y. Wu, W.-M. Yang, C.-L. Chang, Y.-H. Lai, P.-H. Ho, C. F. Kwok, and L.-T. Ho Angiotensin II Enhances Insulin Sensitivity in Vitro and in Vivo Endocrinology, May 1, 2005; 146(5): 2246 - 2254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Yilmaz, A. Sonmez, S. Kilic, T. Celik, N. Bingol, M. Pinar, T. Mumcuoglu, and M. Ozata The association of plasma adiponectin levels with hypertensive retinopathy Eur. J. Endocrinol., February 1, 2005; 152(2): 233 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Schulze, I. Shai, E. B. Rimm, T. Li, N. Rifai, and F. B. Hu Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes Diabetes, February 1, 2005; 54(2): 534 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guebre-Egziabher, J. Bernhard, T. Funahashi, A. Hadj-Aissa, and D. Fouque Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function Nephrol. Dial. Transplant., January 1, 2005; 20(1): 129 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad and A. A. Quyyumi Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome Circulation, September 14, 2004; 110(11): 1507 - 1512. [Full Text] [PDF]
|
|
|
|
|
|
M. Furuhashi, N. Ura, N. Moniwa, Y. Shinshi, H. Kouzu, M. Nishihara, N. Kokubu, T. Takahashi, K.-i. Sakamoto, M. Hayashi, et al. Possible Impairment of Transcardiac Utilization of Adiponectin in Patients With Type 2 Diabetes Diabetes Care, September 1, 2004; 27(9): 2217 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bacci, C. Menzaghi, T. Ercolino, X. Ma, A. Rauseo, L. Salvemini, C. Vigna, R. Fanelli, U. Di Mario, A. Doria, et al. The +276 G/T Single Nucleotide Polymorphism of the Adiponectin Gene Is Associated With Coronary Artery Disease in Type 2 Diabetic Patients Diabetes Care, August 1, 2004; 27(8): 2015 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Schulze, E. B. Rimm, I. Shai, N. Rifai, and F. B. Hu Relationship Between Adiponectin and Glycemic Control, Blood Lipids, and Inflammatory Markers in Men With Type 2 Diabetes Diabetes Care, July 1, 2004; 27(7): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Sharma Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension? Hypertension, July 1, 2004; 44(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwashima, T. Katsuya, K. Ishikawa, N. Ouchi, M. Ohishi, K. Sugimoto, Y. Fu, M. Motone, K. Yamamoto, A. Matsuo, et al. Hypoadiponectinemia Is an Independent Risk Factor for Hypertension Hypertension, June 1, 2004; 43(6): 1318 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sierksma, H. Patel, N. Ouchi, S. Kihara, T. Funahashi, R. J. Heine, D. E. Grobbee, C. Kluft, and H. F.J. Hendriks Effect of Moderate Alcohol Consumption on Adiponectin, Tumor Necrosis Factor-{alpha}, and Insulin Sensitivity Diabetes Care, January 1, 2004; 27(1): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nagasaka, A. Taniguchi, Y. Aiso, T. Yatagai, T. Nakamura, Y. Nakai, M. Fukushima, A. Kuroe, and S. Ishibashi Glimepiride and Serum Adiponectin Level in Type 2 Diabetic Subjects: Response to Yoshioka, Yoshida, and Yoshikawa Diabetes Care, December 1, 2003; 26(12): 3361 - 3361. [Full Text] [PDF]
|
|